COMMUNIQUÉS West-GlobeNewswire

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
26/02/2026
Study met primary endpoint (p-value = 0.012) First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application [...]
InnoCare Announces Key Developments of Critical Clinical Studies
26/02/2026
BEIJING, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today key clinical development [...]
Codetta Bio Announces Commercial Availability of Concerto™ System and New Customizable Cytokine and Neuroscience Panels at AGBT 2026
26/02/2026
ORLANDO, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Codetta Bio™, a leader in multi-omic solutions that combine ultrasensitive protein quantification with simultaneous RNA and DNA analysis, today announced major product [...]
Considering MEDVi QUAD in 2026? Read This Before Enrolling in Any Compounded ED Telehealth Program
26/02/2026
An informational overview of publicly available disclosures, regulatory context, and verification steps consumers commonly review before starting compounded erectile dysfunction treatment through telehealth. NEWARK, DE [...]
MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001
26/02/2026
SHANGHAI, China, Feb. 25, 2026 (GLOBE NEWSWIRE) -- MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first patient has been dosed in the Phase III [...]
Considering MEDVi Tirzepatide GLP-1 Weight Loss in 2026? Read This Before Enrolling in Any Tirzepatide GLP-1 Telehealth Weight Loss Program
26/02/2026
An independent informational overview of MEDVi's compounded tirzepatide telehealth program, including regulatory classification, platform structure, pricing disclosures, and key consumer verification steps. NEWARK, DE, [...]
Palvella Therapeutics Announces Pricing of Upsized Public Offering
26/02/2026
WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat [...]
Sprout Health GLP-1 Weight Loss in 2026 — Compounded Semaglutide Pricing, FDA Status, and What To Know Before Starting a Telehealth GLP-1 Program
26/02/2026
An Independent Informational Overview Examining Sprout Health's Compounded GLP-1 Telehealth Model, Semaglutide and Tirzepatide Program Costs, FDA Regulatory Classification, and Consumer Verification Considerations for [...]
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
26/02/2026
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
25/02/2026
Q4 2025 net product revenue for ZORYVE ® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025 Full year 2025 net product revenue for ZORYVE was $372.1 million, an [...]
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
25/02/2026
Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10 , Respectively Fourth Quarter Adjusted EBITDA 1 was $29 [...]
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
25/02/2026
FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be [...]
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
25/02/2026
GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
25/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
25/02/2026
LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46 th Annual Health Care Conference [...]
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
25/02/2026
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
LeMaitre Q4 2025 Financial Results
25/02/2026
BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0. [...]
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
25/02/2026
Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027 Phase 3 [...]
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
25/02/2026
FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income ( 1) of $161 Million, [...]

Pages